Atreca Inc (PK:BCEL)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 835 Industrial Road
, 75 SHOREWAY ROAD, SUITE C
SAN CARLOS CA 94070
Tel: N/A
Website: https://www.atreca.com
IR: See website
<
Key People
John A. Orwin
President, Chief Executive Officer, Principal Financial Officer, Director 		Tito A. Serafini
Co-Founder, Director 		Rick Ruiz
Principal Accounting Officer
Courtney J. Phillips
General Counsel, Corporate Secretary 		Philippe Bishop
Chief Medical Officer 		 
Business Overview
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Financial Overview
For the nine months ended 30 September 2023, Atreca Inc revenues was not reported. Net loss increased 1% to $76.4M. Higher net loss reflects Biopharmaceutical segment loss increase from $28M to $56.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.97 to -$1.95.
Employees: 90 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$73.46M as of Sep 30, 2023
Net annual income (TTM): -$97.76M as of Sep 30, 2023
Free cash flow (TTM): -$65.39M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 45,153,725 as of Apr 16, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More